Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment

International Journal of Impotence Research volume 19, pages 544–550 (2007)Cite this article

Abstract

Recent large-scale epidemiological studies have documented a strong association between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). This observation has two important scientific and clinical aspects: (i) to reveal the pathomechanism linking LUTS and ED and (ii) to consider this fact in the individual approach for diagnosis and management of these two disorders. The following hypotheses are under investigation to explain the relation between LUTS and ED: (i) an increased Rho-kinase activation, (ii) an α-adrenergic receptor imbalance, (iii) a decrease of NOS/NO in the endothelium, (iv) atherosclerosis affecting the small pelvis and (v) an autonomic hyperactivity, each affecting simultaneously bladder, prostate and penis. According to a recent randomized trial, sildenafil has a positive effect on LUTS yet not on uroflowmetry in men with LUTS and ED. Although further trials are mandatory, phosphodiesterase-5 inhibitors might play a role in the management of LUTS in the future. α-Blockers have no relevant effect on erectile function, tamsulosin leads to retrograde ejaculation in up to 10%. 5α-Reductase inhibitors are associated with ED, loss of libido and reduction of ejaculate volume in up to 10%. Transurethral and open prostatectomy induce retrograde ejaculation in up to 90% of patients while their impact on erectile function is still controversially discussed. Minimal invasive treatment options (laser prostatectomy, transurethral microwave thermotherapy) have a lower rate of retrograde ejaculation in the range of 20–70%. LUTS and ED are strongly linked although the exact mechanism is poorly understood. Men seeking for help for LUTS/benign prostatic hyperplasia should be assessed for different aspects of sexual dysfunction and informed regarding the impact of medication and surgery on sexual health.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Lue TF . Erectile Dysfunction. N Engl J Med 2000; 342: 1802–1813.

    Article  CAS  Google Scholar 

  2. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al. EAU guidelines on erectile dysfunction. Eur Urol 2006; 49: 806–815.

    Article  Google Scholar 

  3. Madersbacher S, Alivizatos G, Rioja Sanz C, Nordling J, Emberton M, Gravas S et al. EAU guidelines on benign prostatic hyperlpasia. Eur Urol 2004; 46: 547–554.

    Article  Google Scholar 

  4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  5. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH . Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘aging male’ symptoms? Results of the ‘cologne male survey’. Eur Urol 2003; 44: 588–594.

    Article  CAS  Google Scholar 

  6. Nicolosi A, Glasser DB, Moreira ED, Villa M . Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res 2003; 15: 253–257.

    Article  CAS  Google Scholar 

  7. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.

    Article  Google Scholar 

  8. Vallancien G, Emberton M, Harving N, van Moorselaar RJ, Alf-One Study Group. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–2261.

    Article  Google Scholar 

  9. Boyle P, Robertson C, Mazzetta C, Keech M . The association between lower urinary tract symptoms and erectile dysfunction in four centres; the UrEpik study. BJU Int 2003; 92: 719–725.

    Article  CAS  Google Scholar 

  10. Hansen BL . Lower urinary tract symptoms and sexual function in both sexes. Eur Urol 2004; 46: 229–234.

    Article  Google Scholar 

  11. Ponholzer A, Temml C, Obermayr R, Madersbacher S . Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004; 64: 772–776.

    Article  Google Scholar 

  12. Terai A, Ichioka K, Matsui Y, Yoshimura K . Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004; 64: 132–136.

    Article  Google Scholar 

  13. Shiri R, Hakkinen JT, Hakama M, Huhtala H, Auvinen A, Tammela TL et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 2005; 174: 205–209.

    Article  Google Scholar 

  14. Lukacs B, Leplege A, Thibault B, Jardin A . Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996; 48: 731–740.

    Article  CAS  Google Scholar 

  15. McVary KT . Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845.

    Article  Google Scholar 

  16. Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L . Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 2003; 285: 990–997.

    Article  Google Scholar 

  17. Rosen R, Giuliano F, Carson C . Sexual dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia. Eur Urol 2005; 47: 824–837.

    Article  Google Scholar 

  18. McVary KT, McKenna KE . The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical and basic science evidence. Curr Urol Rep 2004; 5: 251–257.

    Article  Google Scholar 

  19. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC . Sildenafil improves lower urinary tract symptoms. BJU Int 2002; 90: 836–839.

    Article  CAS  Google Scholar 

  20. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ . Age related erectile and voiding dysfunction: the role of arterial insufficiency. BJU 1998; 82: 26–33.

    Article  Google Scholar 

  21. Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S . The association between LUTS and vascular risk factors in both sexes. Eur Urol 2006; 50: 581–586.

    Article  Google Scholar 

  22. Medina JJ, Parra RO, Moore RG . Benign prostatic hyperplasia (the aging prostate). Med Clin North Am 1999; 83: 1213–1229.

    Article  CAS  Google Scholar 

  23. Reilly CM, Stopper VS, Mills TM . Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997; 18: 26–31.

    CAS  PubMed  Google Scholar 

  24. McVary KT, Razzaq A, Lee C . Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51: 99–107.

    Article  CAS  Google Scholar 

  25. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE . Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol reprod 1994; 51: 99–107.

    Article  CAS  Google Scholar 

  26. Heidler S, Temml C, Broessner C, Mock K, Rauchenwald M, Madersbacher S et al. Is the metabolic syndrome an independent risk factor for ED? J Urol 2007; 177: 651–654.

    Article  Google Scholar 

  27. Mulhall JP, Guhring P, Parker M, Hopps C . Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662–667.

    Article  CAS  Google Scholar 

  28. McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–1077.

    Article  CAS  Google Scholar 

  29. AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530–547.

    Article  Google Scholar 

  30. Giuliano F . Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97 (Suppl 2): 34–38.

    Article  Google Scholar 

  31. Carson CC . Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97 (Suppl 2): 39–43.

    Article  CAS  Google Scholar 

  32. van Moorselaar JRA, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, for the Alf-one study group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95: 603–608.

    Article  Google Scholar 

  33. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001 ARIA 3002 and ARIA 3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with BPH. Urology 2002; 60: 434–441.

    Article  Google Scholar 

  34. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, for the MTOPS research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med 2003; 349: 2387–2398.

    Article  CAS  Google Scholar 

  35. Auersbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB . Simultaneus administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64: 998–1004.

    Article  Google Scholar 

  36. Giuliano F, Kaplan SA, Cabanis MJ, Astruc B . Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006; 67: 1199–1204.

    Article  Google Scholar 

  37. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG . Comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The veterans affairs cooperative study group on transurethral resection of the prostate. N Engl J Med 1995; 332: 75–79.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology and Andrology, Donauspital, Vienna, Austria

    A Ponholzer & S Madersbacher

Authors
  1. A Ponholzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Madersbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Madersbacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ponholzer, A., Madersbacher, S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res 19, 544–550 (2007). https://doi.org/10.1038/sj.ijir.3901578

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901578

Keywords

This article is cited by

Search

Advanced search

Quick links